Abstract
Consortia have begun to establish 'mechanism-based taxonomies' for inflammatory and neurodegenerative diseases that could aid drug development and personalized therapy.
References
Kola, I. & Bell. J. A call to reform the taxonomy of human disease. Nature Rev. Drug Discov. 10, 641–642 (2011).
Mok, T. S. et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Hofmann-Apitius, M., Alarcón-Riquelme, M., Chamberlain, C. et al. Towards the taxonomy of human disease. Nat Rev Drug Discov 14, 75–76 (2015). https://doi.org/10.1038/nrd4537
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4537
- Springer Nature Limited
This article is cited by
-
Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis
Journal of Translational Medicine (2023)
-
Nurse-led care for the management of rheumatoid arthritis: a review of the global literature and proposed strategies for implementation in Africa and the Middle East
Rheumatology International (2021)
-
Klinische, pathologische und molekulare Biomarker der Hidradenitis suppurativa/Acne inversa
Der Hautarzt (2021)
-
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Journal of Translational Medicine (2018)
-
‘Big data’ in mental health research: current status and emerging possibilities
Social Psychiatry and Psychiatric Epidemiology (2016)